CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
IPO Year:
Exchange: NASDAQ
Website: casipharmaceuticals.com
6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
EFFECT - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
F-3/A - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
F-3 - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
S-8 - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
D - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
BTIG Research initiated coverage of CASI Pharma with a rating of Buy and set a new price target of $4.00
HC Wainwright & Co. reiterated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.50 previously
Mizuho initiated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $3.80
BEIJING, July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capi
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024.Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases. We just announced the Center for Drug Evaluation (CDE) of China's Nationa
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2 study of CID-103 in adults patients with chronic Immune Thrombocytopenia (ITP) in China. This China study is part of the global study that was approved by the US FDA in May 2024.CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that ha
BEIJING, Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, at the Lotte New York Palace in New York City. Members of the CASI management team, including Chief Financial Officer Daniel Lang, MD, and Chief Medical Officer Alexander Zukiwski, MD, will host 1x1 investor meetings at the conference.
BEIJING, Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended June 30, 2024. "The second quarter of 2024 was a period of significant progress for CASI as we shifted our Company's strategy to the development of therapeutics for organ transplant rejection and autoimmune disease," said Dr. Wei-Wu He,
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
BEIJING, July 19, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link: https://www.sec.gov/Archives/edgar/data/1962738/000110465924080958/tm2419826d1_6k.htm About CASI Pharmaceuticals CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on d
BEIJING, July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capi
BEIJING, June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that the Company is planning to submit an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for CID-103 for the treatment of antibody-mediated rejection ("AMR") in kidney transplant recipients by the end of 2024. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that has demonstrated an encouraging preclinical efficacy and safety profile compared to other
BEIJING, June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that it has entered into securities purchase agreements with certain investors for a private investment in public equity financing (the "PIPE Transaction") that is expected to result in aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other private placement expenses. The
BEIJING, May 15, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP). On May 13, 2024 CASI received a letter from FDA indicating that study may proceed. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique. E
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical deve
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Proposal To Acquire Its China Business For Aggregate Purchase Price Of $40M MEDS: 34% | TRxADE HEALTH shares are trading higher. The company reported Q1 financial results. RXRX: -21% | Recursion Pharmaceuticals Announced The Pricing Of Its Underwritten Public Offering Of 30,769,230 Shares Of Its Class A Common Stock At A Price To The Public Of $6.50 Per Share
Gainers DermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million. Sarepta Therapeutics (NASDAQ:SRPT) shares rose 39.26% to $171.99. The market value of their outstanding shares is at $16.2 billion. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 17.78% to $0.32. The market value of their outstanding shares is at $17.9 million. Solid Biosciences (NASDAQ:SLDB) stock moved upwards by 17.3% to $7.39. The market value of their outstanding shares is at $283.6 million. ASLAN Pharma (NASDAQ:ASLN) stock rose 14.06% to $0.36. The market value of their outstanding shares is at $8.2 million. Alaunos
Gainers Molecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. Zentalis Pharma (NASDAQ:ZNTL) stock rose 36.83% to $5.67. The market value of their outstanding shares is at $402.2 million. Femasys (NASDAQ:FEMY) stock increased by 28.27% to $1.23. The market value of their outstanding shares is at $27.2 million. SeaStar Medical Holding (NASDAQ:ICU) shares rose 18.68% to $4.89. The market value of their outstanding shares is at $15.2 million. Nanoviricides (AMEX:NNVC) shares rose 17.68% to $1.93. The company's market cap stands at $22.8 million. CASI Pharmaceuticals (NASDAQ:CASI) sha
HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $12 to $6.
Gainers SINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 days ago. Arcutis Biotherapeutics (NASDAQ:ARQT) stock increased by 18.92% to $9.67. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. MultiPlan (NYSE:MPLN) stock increased by 17.24% to $0.66. The market value of their outstanding shares is at $426.5 million. CASI Pharmaceuticals (NASDAQ:CASI) shares moved upwards by 15.45% to $3.66. The company's market cap stands at $49.0 million. As per the press release, Q1 earnings
SC 13G/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)
SC 13D/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)
SC 13G - CASI Pharmaceuticals, Inc. (0001962738) (Subject)
SC 13G - CASI Pharmaceuticals, Inc. (0001962738) (Subject)
SC 13G/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)
SC 13D/A - CASI Pharmaceuticals, Inc. (0000895051) (Subject)
SC 13D/A - CASI Pharmaceuticals, Inc. (0000895051) (Subject)
SC 13G/A - CASI Pharmaceuticals, Inc. (0000895051) (Subject)
SC 13D/A - CASI Pharmaceuticals, Inc. (0000895051) (Subject)
SC 13D/A - CASI Pharmaceuticals, Inc. (0000895051) (Subject)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe
BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the United States ("US") CB-5339 Investigational New Drug ("IND") application.
~ CASI Pharmaceuticals acquires global rights to CB-5339, a clinical stage VCP/p97 inhibitor in development for oncology indications ~ Eikon Therapeutics acquires pre-clinical assets spanning multiple targets Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals (NASDAQ:CASI) has acquired the global rights to the company's clinical asset, CB-5339, and Eikon Therapeutics has acquired rights to the company's pre-clinical assets. CASI Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. Eikon Therapeutics is a clinical-stage company work
ROCKVILLE, Md. and BEIJING, Aug. 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the second quarter of 2022. Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $8.6 million in EVOMELA® sales revenue for the second quarter of 2022. This is an increase of 19% compared to the same period last year. Our sales and marketing team is proven to be resilien
ROCKVILLE, Md. and BEIJING, Aug. 5, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the second quarter of 2022, at 8:00 A.M. EST on Friday, August 12th, 2022. On the call, CASI's Chairman & CEO will provide an update on the Company's business and upcoming milestones. The conference call can be accessed by dialing 1-866-218-2402 (U.S.) or 1-412-90
ROCKVILLE, Md. and BEIJING, May 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2022. Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $9.0 million in EVOMELA® sales revenue for the first quarter of 2022. This is an increase of 58% compared to the same period last year. Our first commercial product, EVOMELA has been instrumen
ROCKVILLE, Md. and BEIJING, May 2, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the first quarter of 2022, at 8:00 a.m. EST on Thursday, May 12th, 2022. On the call, CASI's Chairman & CEO will provide an update on the Company's business and upcoming milestones. The conference call can be accessed by dialing 1-866-218-2402 (U.S.) or 1-412-902-6
ROCKVILLE, Md. and BEIJING, March 23, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the fourth quarter and for the year ended December 31st, 2021, at 8:00 a.m. EDT on Monday, March 28th, 2022. On the call, CASI's Chairman & CEO will provide an update on the Company's business and upcoming milestones. The conference call can be accessed by diali
ROCKVILLE, Md. and BEIJING, Nov. 12, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the third quarter of 2021. Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $8.1 million in EVOMELA® revenues for the quarter. We remain confident in our guidance for our full-year 2021 revenue growth to exceed 2020 revenues by over 80%. This continued growth furt